1.40
price up icon0.00%   0.00
 
loading
Schlusskurs vom Vortag:
$1.40
Offen:
$1.42
24-Stunden-Volumen:
39,471
Relative Volume:
0.70
Marktkapitalisierung:
$13.80M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-18.98M
KGV:
-0.4906
EPS:
-2.8535
Netto-Cashflow:
$-14.55M
1W Leistung:
+16.67%
1M Leistung:
+27.27%
6M Leistung:
-2.78%
1J Leistung:
-38.86%
1-Tages-Spanne:
Value
$1.3421
$1.46
1-Wochen-Bereich:
Value
$1.19
$1.46
52-Wochen-Spanne:
Value
$0.88
$2.73

In 8 Bio Inc Stock (INAB) Company Profile

Name
Firmenname
In 8 Bio Inc
Name
Telefon
(646) 600-6438
Name
Adresse
EMPIRE STATE BUILDING, NEW YORK
Name
Mitarbeiter
18
Name
Twitter
Name
Nächster Verdiensttermin
2026-11-05
Name
Neueste SEC-Einreichungen
Name
INAB's Discussions on Twitter

Compare INAB vs VRTX, MRNA, REGN, ARGX, RVMD

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
INAB icon
INAB
In 8 Bio Inc
1.40 11.83M 0 -18.98M -14.55M -2.8535
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
504.73 133.37B 12.34B 4.34B 3.71B 16.87
MRNA icon
MRNA
Moderna Inc
190.01 79.40B 2.23B -3.19B -1.60B -8.1462
REGN icon
REGN
Regeneron Pharmaceuticals Inc
735.20 81.13B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
919.21 60.03B 4.16B 1.29B 734.26M 19.58
RVMD icon
RVMD
Revolution Medicines Inc
206.64 43.93B 742.00K -1.37B -1.07B -7.0731

In 8 Bio Inc Stock (INAB) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-03-18 Eingeleitet Laidlaw Buy
2022-08-30 Eingeleitet H.C. Wainwright Buy

In 8 Bio Inc Aktie (INAB) Neueste Nachrichten

pulisher
Oct 01, 2026

Valion Bio Announces Completion of Entolimod Oral Mucosal Formulation Development - kalkinemedia.com

Oct 01, 2026
pulisher
Oct 01, 2026

Doctors will present 24-month results from a teen eye-disease trial in New Orleans. - Stock Titan

Oct 01, 2026
pulisher
Sep 30, 2026

After 16 weeks off treatment, Q32 Bio (QTTB) reports results from its 33-patient hair-loss trial. - Stock Titan

Sep 30, 2026
pulisher
Sep 28, 2026

A shareholder falls below 5% in Gossamer Bio (GOSS) after a reverse stock split. - Stock Titan

Sep 28, 2026
pulisher
Sep 28, 2026

GRI Bio, Inc. SEC Filing (Sep 28, 2026) - Stock Titan

Sep 28, 2026
pulisher
Sep 28, 2026

Gossamer Bio regains Nasdaq compliance after 1-for-80 reverse stock split - TradingView

Sep 28, 2026
pulisher
Sep 25, 2026

Q32 Bio Inc. (QTTB) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com

Sep 25, 2026
pulisher
Sep 25, 2026

Data on a possible lupus treatment are due Monday - Stock Titan

Sep 25, 2026
pulisher
Sep 24, 2026

After a 1-for-25 reverse stock split, Valion Bio (VBIO) executive reports a stock-unit settlement. - stocktitan.net

Sep 24, 2026
pulisher
Sep 24, 2026

Stocks in play: Avai Bio Inc - The Globe and Mail

Sep 24, 2026
pulisher
Sep 22, 2026

IN8bio to Present at Sidoti Small-Cap Virtual Conference - GlobeNewswire Inc.

Sep 22, 2026
pulisher
Sep 18, 2026

TELA Bio Received Notice of Delisting - TradingView

Sep 18, 2026
pulisher
Sep 17, 2026

Upstream Bio (UPB) exec offloads shares to cover taxes - Stock Titan

Sep 17, 2026
pulisher
Sep 17, 2026

Inmune Bio (NASDAQ: INMB) grants 100,000 stock options to new director - Stock Titan

Sep 17, 2026
pulisher
Sep 14, 2026

$2.50 share warrants bring new cash to Cabaletta Bio (CABA) - Stock Titan

Sep 14, 2026
pulisher
Sep 14, 2026

700,000 face alopecia as Q32 Bio (QTTB) hires drug veterans - Stock Titan

Sep 14, 2026
pulisher
Sep 10, 2026

Kala Bio Secures 5-Year Exclusive U.S. Distribution for Ophthalmic Genetic Testing With Virotek - tradingview.com

Sep 10, 2026
pulisher
Sep 10, 2026

Senior finance VP at Korro Bio (KRRO) sells 7,353 shares under 10b5-1 trading plan - Stock Titan

Sep 10, 2026
pulisher
Sep 09, 2026

Kyntra Bio (KYNB) CFO holds 4,355 shares after tax withholding - Stock Titan

Sep 09, 2026
pulisher
Sep 09, 2026

KALA BIO (NASDAQ: KALA) sets Sept. 19 cutoff for 2026 shareholder proposals - Stock Titan

Sep 09, 2026
pulisher
Sep 08, 2026

Braveheart Bio Completes IPO with $122.8 Million in Gross Proceeds - Minichart

Sep 08, 2026
pulisher
Sep 08, 2026

Adicet Bio posts September 2026 investor presentation outlining prula-cel and ADI-212 clinical timelines - TradingView

Sep 08, 2026
pulisher
Sep 08, 2026

Braveheart Bio (NASDAQ:BRVE) Trading Up 8%Should You Buy? - MarketBeat

Sep 08, 2026
pulisher
Sep 08, 2026

PeproMene Bio Announces Publication in The Lancet of Breakthrough Phase 1 Clinical Trial Results Demonstrating Deep and Durable Complete Responses in Relapsed/Refractory B-cell Lymphomas, including after prior CD19 CAR T-cell failure - BioSpace

Sep 08, 2026
pulisher
Sep 08, 2026

GRI Bio posts Phase 2a IPF biomarker and safety data; +99 mL placebo‑adj FVC, supports longer study - TradingView

Sep 08, 2026
pulisher
Sep 08, 2026

Experimental IPF pill from GRI Bio (GRI) boosts lung function in 12 weeks as company eyes 52-week study - stocktitan.net

Sep 08, 2026
pulisher
Sep 08, 2026

Cough during treatment was 0% with GRI Bio's drug, versus 25% on placebo - stocktitan.net

Sep 08, 2026
pulisher
Sep 08, 2026

symbol__ Stock Quote Price and Forecast - CNN

Sep 08, 2026
pulisher
Sep 04, 2026

Investor group in Valion Bio (VBIO) shifts to passive stake - Stock Titan

Sep 04, 2026
pulisher
Sep 03, 2026

[425] Passage BIO, Inc. Business Combination Communication | PASG SEC FilingForm 425 - Stock Titan

Sep 03, 2026
pulisher
Sep 01, 2026

Valion Bio Raises $7.74 Million Via Series B/C Preferred and Warrants From 3i - TradingView

Sep 01, 2026
pulisher
Aug 28, 2026

2,426,857 Boundless Bio (NASDAQ: BOLD) shares held by Zachary Hornby - stocktitan.net

Aug 28, 2026
pulisher
Aug 28, 2026

KALA BIO Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView

Aug 28, 2026
pulisher
Aug 27, 2026

FDA clears Adicet Bio's application to study a gene-edited prostate cancer therapy - Stock Titan

Aug 27, 2026
pulisher
Aug 26, 2026

Gossamer Bio (NASDAQ: GOSS) links CEO options to FDA decision on seralutinib - Stock Titan

Aug 26, 2026
pulisher
Aug 24, 2026

Valion Bio, Inc. SEC Filing (Aug 24, 2026) - Stock Titan

Aug 24, 2026
pulisher
Aug 24, 2026

Gossamer Bio (NASDAQ: GOSS) has 6% of its stock under D. E. Shaw’s reported influence - Stock Titan

Aug 24, 2026
pulisher
Aug 22, 2026

TBIO | TELESIS BIO INC Insider Trading - Quiver Quantitative

Aug 22, 2026
pulisher
Aug 21, 2026

Gossamer Bio Lines Up Up To $250 Million Private Placement With Milestone-Triggered Warrants - TradingView

Aug 21, 2026
pulisher
Aug 19, 2026

3i injects cash into Valion Bio (VBIO) under tight ownership cap - Stock Titan

Aug 19, 2026
pulisher
Aug 19, 2026

Climb Bio Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs

Aug 19, 2026
pulisher
Aug 15, 2026

Tech workers may be better off selling their company stock - Business Insider

Aug 15, 2026
pulisher
Aug 14, 2026

TELA Bio (TELA) stake: Nantahala group reports 12.94% ownership of 5.79M shares - Stock Titan

Aug 14, 2026
pulisher
Aug 14, 2026

Palisade Bio (PALI): Commodore Capital group now reports 0.0% beneficial ownership - Stock Titan

Aug 14, 2026
pulisher
Aug 14, 2026

Climb Bio, Inc. (CLYM): MPM BioImpact LLC reports 0% ownership in amendment - Stock Titan

Aug 14, 2026
pulisher
Aug 14, 2026

Point72 discloses 4.95% Q32 Bio Inc. (QTTB) holding in Schedule 13G/A - Stock Titan

Aug 14, 2026
pulisher
Aug 14, 2026

Highbridge Capital (ANVS) discloses 6.1% Annovis Bio stake tied to 2.78M warrant shares - Stock Titan

Aug 14, 2026
pulisher
Aug 14, 2026

Cabaletta Bio (CABA): T. Rowe Price reports 11.6% common stock stake - Stock Titan

Aug 14, 2026
pulisher
Aug 14, 2026

Q32 Bio Inc. (QTTB) major holders cut reported stake to 0% - Stock Titan

Aug 14, 2026
pulisher
Aug 14, 2026

Caballeta Bio (CABA) stake: Bain Capital Life Sciences reports 9.99% position - Stock Titan

Aug 14, 2026
pulisher
Aug 13, 2026

Korro Bio (KRRO) director-affiliated funds sell 2,143 shares under 10b5-1 plan - Stock Titan

Aug 13, 2026

Finanzdaten der In 8 Bio Inc-Aktie (INAB)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$96.90
price up icon 0.05%
$57.16
price down icon 0.82%
$35.72
price up icon 0.62%
$219.72
price down icon 4.96%
ONC ONC
$358.07
price down icon 0.20%
$206.64
price up icon 0.36%
Kapitalisierung:     |  Volumen (24h):